Short answer
OptimizeRx Corp (OPRX) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $20M (down 9.5% year over year) with net income of −$495,000.
Q1 2026 key financials · XBRL
- Revenue
- $20M
- −9.5% YoY
- Net income
- −$495,000
- +77.5% YoY
- Operating margin
- 2.0%
- EPS (diluted)
- −$0.03
- +75.0% YoY
Source: XBRL data from the OptimizeRx Corp (OPRX) Q1 2026 10-Q on SEC EDGAR. USD.
OptimizeRx Corp Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $19,844, down 10% YoY from $21,928, driven by $3,400 managed-service decline
- Operating margin 2.0% vs negative 9.6% YoY; net loss margin negative 2.5% vs negative 10.0%
- Higher-margin solutions best-performing mix; managed services worst, with cost-of-revenue margin 25% vs 39%
- Operating cash flow negative $467 vs positive $3,864 YoY; cash decreased $3,196
- $2,708 financing cash outflow, including debt repayment; $10,000 share-repurchase authorization
- Outlook: sufficient liquidity for twelve months, with customer spending pressured by macroeconomic uncertainty and MFN negotiations
Risk Factors
- No material changes in risk factors from December 31, 2025 Form 10-K
- Leadership transition risk from Chief Commercial Officer separation effective June 15, 2026
- Regulatory compliance risk from pending separation and advisory agreement disclosure
- Financing risk under Amendment No. 4 to Financing Agreement dated March 2, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OptimizeRx Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.